DGAP-News

Carl Zeiss Meditec AG: At the ESCRS 2014 ZEISS is offering cataract surgeons a greater diversity of products for enhanced safety and presenting a new product line for basic diagnostics - Seite 3

each and every patient."

A further focus of this year's ZEISS presentation at the meeting is on the
products for refractive surgery. "The needs of doctors and patients in
refractive laser surgery are very different. To cater to this diversity, we
also offer a broad product portfolio," says Ludwin Monz. This includes the
MEL(R) 80 and MEL(R) 90 excimer lasers and the VisuMax(R) femtosecond
laser. According to Monz, the strong demand for SMILE technique is clear
confirmation of the company's policy: more than 125,000 procedures have
already been successfully performed worldwide; 400 trained doctors offer
the treatment in more than 230 facilities in 38 countries. The approval
procedure in the USA is also proceeding positively. Before the start of the
ESCRS, more than 330 persons will have already been treated as part of the
clinical trials being conducted in the US.

Visit us at booth at the ZEISS booth E14. You can find further information
on our product innovations and events at the ESCRS at
www.meditec.zeiss.com/escrs-2014

1: Maedel S et al. Effect of heparin coating of a foldable intraocular lens
on inflammation and capsular bag performance after cataract surgery. JCRS
2013

Press contact:
Jann Gerrit Ohlendorf, Group Communications, Carl Zeiss Meditec AG
Phone [phone], Email: [e-mail]

Contact for investors:
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone [phone], Email: [e-mail]

www.meditec.zeiss.com/press

Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's leading
medical technology companies. The company supplies innovative technologies
and application-oriented solutions designed to help doctors improve the
quality of life of their patients. The company offers complete solutions,
including implants and consumables, to diagnose and treat eye diseases. The
company creates innovative visualization solutions in the field of
microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded
off by promising, future-oriented technologies such as intraoperative
radiotherapy. In fiscal year 2012/2013 (ended 30 September) the company's
around 2,500 employees generated revenue of EUR 906 million. Carl Zeiss
Meditec headquarters are located in Jena, Germany.
The company has subsidiaries in Germany and abroad; more than 50 percent of
its employees are based in the USA, Japan, Spain and France. The Center for
Application and Research in India (CARIn) in Bangalore, India, and the Carl
Zeiss Innovation Center for Research and Development in Shanghai, China,